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ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln
Polymorphisms Are Independent Prognostic Factors
for the Clinical Course of Melanoma
David Schrama1,2, Dominique Scherer3, Michael Schneider1, Marc Zapatka4, Eva-Bettina Bro¨cker1,
Dirk Schadendorf5, Selma Ugurel1,2, Rajiv Kumar3 and Ju¨rgen C. Becker2
Genetic variants in DNA repair enzymes contribute to the susceptibility to cutaneous melanoma; consequently,
we analyzed whether common nonsynonymous single-nucleotide polymorphisms in DNA repair enzyme genes
might also influence the course of disease. To this end, we determined eight polymorphisms of seven different
DNA repair enzymes in 742 patients with cutaneous melanoma, and correlated these with overall survival.
Univariate Cox proportional hazards model analyses revealed that ERCC5 (XPG) 1104 His/His was significantly
associated with impaired survival. Indeed, the univariate hazard ratio (HR) was 2.8 times higher for patients
with ERCC5 1104 His/His (Po0.001) compared with ERCC5 1104 Asp/Asp. Accordingly, the 5-year survival rate was
55% (95% confidence interval 43–71) for patients with ERCC5 1104 His/His, whereas 82% (95% confidence
interval 78–86) of patients with ERCC5 1104 Asp/Asp were still alive at this time. Importantly, adjusted Cox
regression analysis not only confirmed ERCC5 1104 His/His as an independent prognostic factor (multivariate
HR¼ 4.5; Po0.001), but also revealed the significant impact of ERCC2 (XPD) 751 Gln/Gln on prognosis, with a
2.2-fold increased HR compared with ERCC2 751 Lys/Lys (P¼ 0.009). Thus, ERCC5 codon 1104 and ERCC2 codon
751 polymorphisms are independent prognostic factors in patients with cutaneous melanoma.
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INTRODUCTION
Malignant melanoma is an aggressive cancer with a high
mortality rate once metastasized. One of the major risk
factors for melanoma is sun exposure (Halpern and Altman,
1999). Notably, UV radiation causes various kinds of DNA
damage. UVB, i.e., 280–315 nm, provokes DNA damage by
cyclobutane pyrimidine dimers and pyrimidine photopro-
ducts, whereas wavelengths of 315–400 nm, i.e., UVA, cause
single-strand breaks, DNA–protein crosslinking, and genera-
tion of free oxidative radicals (Pfeifer et al., 2005). As
unrepaired DNA damage can either result in apoptosis or
DNA aberrations leading to unregulated cell growth and
cancer, cells are endued with various DNA repair pathways
that are activated upon DNA damage.
In order to maintain the integrity of the genome, at least
four different pathways of DNA repair operate on specific
types of damaged DNA. For example, base excision repair
(BER) corrects small DNA lesions such as oxidized or
reduced bases, as well as fragmented or nonbulky adducts.
The nucleotide excision repair (NER) pathway repairs bulky
lesions such as pyrimidine dimers, larger chemical adducts,
or DNA crosslinks. In addition, at least two pathways to
repair double-strand breaks exist, i.e., the homologous
recombination pathway and the nonhomologous end-joining
repair pathway (reviewed in Goode et al., 2002).
As maintenance of DNA integrity is important to prevent
carcinogenesis, genes encoding DNA repair molecules are
prime candidates for cancer-susceptibility genes (Bartsch
et al., 2007). Indeed, several single-nucleotide polymorph-
isms (SNPs) in these genes have been implicated in increased
cancer susceptibility (Kiyohara and Yoshimasu, 2007;
Naccarati et al., 2007): e.g., ERCC2 (XPD) 751 Gln and
XRCC3 241 Met are both associated with an increased risk to
develop cutaneous melanoma (Winsey et al., 2000; Li et al.,
2006a). However, genetic variation in DNA repair enzymes
might also affect the clinical course of cancer by, e.g.,
affecting genetic stability (Umar and Kunkel, 1996; Kloor
et al., 2010). Indeed, it has been recently reported that
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primary melanomas overexpressing DNA repair genes are
characterized by an impaired prognosis (Kauffmann et al.,
2008). The authors hypothesized that tumor cells in the
process of metastasis try to replicate in a fast and error-free
mode to maintain those genetic aberrations associated with a
growth advantage. To further extent this notion, we scruti-
nized the prognostic impact of polymorphic variation in DNA
repair genes on the course of melanoma by analyzing eight
SNPs in a cohort of 742 melanoma patients. All of the
addressed SNPs are nonsynonymous. The included SNPs
were xeroderma pigmentosum complementation group C
(XPC) p.Ala499Val and XPC p.Lys939Gln, excision repair
cross-complementing rodent repair deficiency, complemen-
tation group 2 (ERCC2; alias XPD) p.Lys751Gln and ERCC5
(XPG) p.Asp1104His all involved in NER, APEX1 (APEX
nuclease (multifunctional DNA repair enzyme) 1) p.As-
p148Glu and X-ray repair complementing defective repair
in Chinese hamster cells 1 (XRCC1) p.Arg399Gln both
participating in BER and XRCC3 p.Thr241Met and Nijmegen
break syndrome mutated gene (NBN; NBS1) p.Glu185Gln,
i.e., molecules of the homologous recombination repair
pathway. This analysis revealed that ERCC5 p.Asp1104His
and ERCC2 p.Lys751Gln have a significant and independent
impact on the clinical course of melanoma.
RESULTS
Patient characteristics
Of the 742 patients, 328 were female (44. 2%) and 414 male
(55.8%). Superficial spreading melanoma (346 patients) and
nodular melanoma (182 patients) were the most common
histological diagnoses. The median age at diagnosis of the
patient cohort was 54.8 years and the median follow-up time
was 74.2 months. A total of 226 patients died during the
follow-up period. The detailed patient and tumor character-
istics are presented in Table 1.
Genotyping frequencies of polymorphisms and survival
The allelic and genotypic frequencies of SNPs are given in
Table 2. Notably, from the majority of samples the genotype
could be determined; only 4 to 12.9%, with an average
of B7.6%, of samples did not give a distinct result. The
observed genotype frequencies were in the range of the
frequencies reported on the respective SNP database web-
sites of the National Center for Biotechnology Information.
From the analyzed SNPs only XPC p.Lys939Gln and XPC
p.Ala499Val were statistically significant in linkage disequili-
brium after Bonferroni–Holmes adjustment (Po0.001; D’¼
0.906; r2¼ 0.19). This linkage disequilibrium for the two XPC
SNPs has been published previously (Huang et al., 2006).
The effect of each polymorphism on overall survival was
estimated by the Kaplan–Meier method, revealing that ERCC5
p.Asp1104His has a significant impact on overall survival
(Po0.001; log-rank test): ERCC5 1104 His/His was asso-
ciated with a highly impaired prognosis compared with
ERCC5 1104 His/Asp or Asp/Asp (Figure 1). This observation
was confirmed by the 5-year survival rate (Table 3): 153
patients died during the first 5 years after diagnosis, and 469
patients had a follow-up time of 460 months. Validated
prognostic factors such as age, gender, tumor classification,
and clinical stage at diagnosis influenced the 5-year sur-
vival significantly, thereby demonstrating that our cohort
is representative for the general melanoma population
(Balch et al., 2001b). Notably, from the analyzed DNA repair
gene SNPs, only ERCC5 1104 polymorphisms signifi-
cantly influenced the 5-year survival rate. Indeed, the survival
impact was obvious in both the whole patient population and
the gender subgroups. In this regard, the 5-year survival rate
was 82% (95% confidence interval 78–86) for ERCC5 1104
Asp/Asp versus 56% (95% confidence interval 43–71) for His/
His (Po0.001; log-rank test).
Hazard ratio (HR) for DNA repair polymorphisms
Next, we calculated the HRs for DNA repair SNPs by
univariate and multivariate Cox regression analyses. The
univariate analyses confirmed that gender, age, tumor
classification, and stage at diagnosis as well as ERCC5
p.Asp1104His polymorphisms influenced the risk to die from
melanoma (Figure 2). The HR for ERCC5 1104 His/His was
2.8 times higher than for ERCC5 1104 Asp/Asp (Po0.001).
Additionally, the ERCC2 p.Lys751Gln polymorphism, for
which we observed a trend in the 5-year survival analysis,
significantly influenced prognosis: patients with ERCC2 751
Gln/Gln had a 1.7 times increased risk to die compared with
ERCC2 751 Lys/Lys patients (P¼ 0.035). To test whether
ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln are indepen-
dent prognostic factors, we performed multivariate Cox
regression analysis. For this analysis, we adjusted each SNP
to each other as well as to the known prognostic parameters
gender, age, and stage at diagnosis. In order to decrease the
number of patient subgroups, stage IIB and IIC as well as
stage IIIB and IIIC patients were grouped. These analyses
confirmed ERCC5 1104 His/His (HR¼4.5; Po0.001) and
ERCC2 751 Lys/Lys (HR¼ 2.2; P¼0.009) as independent
prognostic factors for overall survival of cutaneous melanoma
patients (Figure 3). All results of the multivariate analyses
were confirmed by bootstrapping, i.e., analysis of randomly
selected patient cohorts.
DISCUSSION
DNA repair is essential to ensure integrity and stability of the
genome. Genetic instability is responsible for the cellular
changes that confer progressive transformation on cancerous
cells; thus, defects in DNA repair can be expected to promote
cancer. Indeed, patients with XP, an autosomal recessive
disease associated with defective NER, have a 1,000-fold
higher susceptibility for skin cancer (Kraemer et al., 2007).
The ability to repair DNA damages, however, also varies to a
considerable extent within the normal human population.
These variations could be a consequence of common
polymorphic amino-acid substitutions in DNA repair genes
(Mohrenweiser et al., 2003). Consequently, many studies
have been performed to reveal possible associations between
SNPs in DNA repair genes and susceptibility to cancer
(Berwick and Vineis, 2000; Goode et al., 2002). Most studies,
however, do not address whether such variations in DNA
repair impact on the clinical course of cancer. Several lines of
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Table 1. Patient characteristics
Variables Total Women Men
Median (IQR) age at diagnosis 54.8 (42.9–66.0) (n=742) 53.7 (40.2–65.9) (n=328) 55.8 (44.8–66.1) (n=414)
Median (IQR) age at death 61.0 (49.0–71.9) (n=226) 58.4 (48.0–72.8) (n=94) 61.5 (50.6–70.8) (n=132)
Median (IQR) follow-up time (months) 74.2 (45.3–114.1) (n=742) 80.8 (51.8–116.7) (n=328) 70.7 (40.1–109.2) (n=414)
Death 226 (30.1%) 94 (28.7%) 132 (31.9%)
Therapy1
Adjuvant IFN 154 (20.8%) 73 (22.3%) 81 (19.6%)
Chemotherapy 213 (28.7%) 89 (27.1%) 124 (30%)
Radiation 84 (11.3%) 37 (11.3) 47 (11.4%)
Immunotherapy 160 (21.6%) 67 (20.4%) 93 (22.5%)
T-classification2
T1a 202 (28.7%) 90 (28.7%) 112 (28.7%)
T1b 13 (1.8%) 4 (1.3%) 9 (2.3%)
T2a 187 (26.6%) 84 (26.8%) 103 (26.4%)
T2b 27 (3.8%) 9 (2.9%) 18 (4.6%)
T3a 126 (17.9%) 66 (21.0%) 60 (15.4%)
T3b 51 (7.2%) 22 (7.0%) 29 (7.4%)
T4a 71 (10.1%) 30 (9.6%) 41 (10.5%)
T4b 27 (3.8%) 9 (2.9%) 18 (4.6%)
Stage at diagnosis2
IA 198 (27.7%) 87 (27.6%) 111 (27.8%)
IB 183 (25.6%) 77 (24.4%) 106 (26.6%)
IIA 134 (18.8%) 65 (20.6%) 69 (17.3%)
IIB 96 (13.4%) 45 (14.3%) 51 (12.8%)
IIC 13 (1.8%) 2 (0.6%) 11 (2.8%)
IIIA 32 (4.5%) 15 (4.8%) 17 (4.3%)
IIIB 44 (6.2%) 18 (5.7%) 26 (6.5%)
IIIC 5 (0.7%) 3 (1.0%) 2 (0.5%)
IV 9 (1.3%) 3 (1.0%) 6 (1.5%)
Histological type
ALM 44 (6.8%) 19 (6.8%) 25 (6.8%)
LMM 37 (5.7%) 15 (5.3%) 22 (6.0%)
NM 182 (28.2%) 77 (27.4%) 105 (28.8%)
SSM 346 (53.6%) 154 (54.8%) 192 (52.6%)
Other 12 (1.9%) 6 (2.1%) 6 (1.6%)
Nonclassifiable 25 (3.9%) 10 (3.6%) 15 (4.1%)
Abbreviations: ALM, acral lentiginous melanoma; IFN, interferon; IQR, interquartile range; LMM, lentigo maligna melanoma; NM, nodular melanoma; SSM,
superficial spreading melanoma.
1Number of patients receiving the respective therapies.
2T-classification of primary tumor as well as pathological staging at diagnosis was performed according to the American Joint Committee on Cancer (AJCC)
Classification from 2002 (Balch et al., 2001a).
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evidence suggest that this may be the case: for melanoma,
genomic instability is not only increased in primary tumors
when compared with nevi, but also in metastases when
compared with primary tumors (Chin et al., 2006); similarly,
hypoxia, which is associated with an aggressive phenotype of
cancer, mediates among other changes genetic instability
(Bristow and Hill, 2008). Thus, we scrutinized whether
common nonsynonomous SNPs in DNA repair genes are
related to the progression of melanoma in a cohort of 4700
melanoma patients for whom detailed information and a
close follow-up was available. The majority of the analyzed
SNPs were selected as they are among the most studied DNA
repair gene SNPs for melanoma susceptibility (Li et al.,
2006a, b; Mocellin et al., 2009). In addition, the NBN SNP
was included as germline mutations have been described for
melanoma (Steffen et al., 2004). Our study revealed that
ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln are indepen-
dent prognostic factors for the clinical course of melanoma.
Interestingly, although ERCC2 SNP has been described
as melanoma susceptibility SNP in one study (Li et al.,
2006a), a large study of almost 1,200 melanoma patients
as well as a review of the literature could not reveal an
impact of these two SNPs on the susceptibility for melanoma
(Figl et al., 2010).
The number of studies addressing the association between
SNPs in DNA repair genes and the course of neoplastic
diseases is surprisingly low, particularly if compared with
those addressing cancer susceptibility. This is probably
because of the fact that the diagnosis of cancer itself is more
widely available than the detailed medical history. Conse-
quently, studies addressing SNPs as prognostic factors are
largely characterized by a low patient number. For example,
in a recent study scrutinizing three DNA repair SNPs, i.e.,
XRCC1 p.Arg399Gln, ERCC2 p.Lys751Gln, and ERCC1
p.Thr118Cys, and their association with survival in stage IV
melanoma patients receiving biochemotherapy, only 90
patients were included (Liu et al., 2005). This analysis,
however, revealed that the ERCC1 polymorphism was weakly
associated with overall survival, and the Gln allele of the
ERCC2 polymorphism was unfavorable without reaching
significance. In contrast to our study, Liu et al. (2005)
searched for a predictive marker, whereas we addressed
Table 2. Results of SNP determination
SNP Allele (AA) Allele frequency Genotypes Patients (frequency) Women (frequency) Men (frequency)
APEX1 p.Asp148Glu T (Asp) 0.52 TT 189 (28.0) 70 (23.4) 119 (31.5)
(rs1130409) G (Glu) 0.48 TG 324 (47.9) 155 (51.8) 169 (44.7)
GG 164 (24.2) 74 (24.7) 90 (23.8)
ERCC2 p.Lys751Gln A (Lys) 0.63 AA 285 (40.2) 122 (38.4) 163 (41.4)
(rs13181) C (Gln) 0.37 AC 329 (46.4) 148 (46.5) 181 (45.9)
CC 98 (13.8) 48 (15.1) 50 (12.7)
ERCC5 p.Asp1104His G (Asp) 0.78 GG 449 (63.1) 204 (63.9) 245 (62.3)
(rs17655) C (His) 0.22 GC 206 (28.9) 91 (28.5) 115 (29.3)
CC 57 (8.0) 24 (7.5) 33 (8.4)
NBN p.Glu185Gln G (Glu) 0.69 GG 329 (48.5) 146 (48.0) 183 (48.8)
(rs1805794) C (Gln) 0.31 GC 282 (41.5) 120 (39.5) 162 (43.2)
CC 68 (10.0) 38 (12.5) 30 (8.0)
XPC p.Ala499Val C (Ala) 0.74 CC 389 (57.1) 168 (55.3) 221 (58.6)
(rs2228000) T (Val) 0.26 CT 236 (34.7) 104 (34.2) 132 (35.0)
TT 56 (8.2) 32 (10.5) 24 (6.4)
XPC p.Lys939Gln A (Lys) 0.6 AA 238 (36.8) 108 (37.4) 130 (36.4)
(rs2228001) C (Gln) 0.4 AC 295 (45.7) 129 (44.6) 166 (46.5)
CC 113 (17.5) 52 (18.0) 61 (17.1)
XRCC1 p.Arg399Gln G (Arg) 0.66 GG 303 (44.1) 139 (44.8) 164 (43.5)
(rs25487) A (Gln) 0.34 GA 302 (44.0) 133 (42.9) 169 (44.8)
AA 82 (11.9) 38 (12.3) 44 (11.7)
XRCC3 p.Thr241Met C (Thr) 0.62 CC 283 (40.7) 118 (37.6) 165 (43.2)
(rs861539) T (Met) 0.38 CT 300 (43.1) 142 (45.2) 158 (41.4)
TT 113 (16.2) 54 (17.2) 59 (15.4)
Abbreviations: AA, amino acid; APEX1, APEX nuclease (multifunctional DNA repair enzyme) 1; ERCC5, excision repair cross-complementing rodent repair
deficiency, complementation group 5; NBN, Nijmegen break syndrome mutated gene; SNP, single-nucleotide polymorphism; XPC, xeroderma
pigmentosum complementation group C; XRCC, X-ray repair complementing defective repair in Chinese hamster cells.
www.jidonline.org 1283
D Schrama et al.
ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln in Melanoma
prognostic markers for melanoma. Moreover, the study of Liu
et al. (2005) is likely to be underpowered to reach a
significant result for ERCC2. Interestingly, ERCC2
p.Lys751Gln was suggested to be a prognostic factor for
melanoma progression, as in 244 Swedish patients the Lys/
Gln phenotype was more frequent in patients with advanced
melanoma (Kertat et al., 2008). In a previous study of 400
melanoma patients, Figl et al. (2009) reported XRCC1
p.Arg399Gln to be associated with prognosis: patients
with XRCC1 Gln/Gln demonstrated a median overall survival
of 24.4 years compared with 11.5 years for the two other
genotypes. In the same study, however, this association was
not detectable in an independent Spanish patient cohort
selected by the same criteria, i.e., only patients first
diagnosed at stage I or II. The authors concluded that this
may have been because of the fact that only a few deaths
were recorded for this cohort. In our study, although the
independent patient cohort reflects the whole variety of
tumor stages at diagnosis translating into a worse survival
rate, we were not able to confirm the previous results. This
observation demonstrates the importance of conducting
multiple studies on potential biomarkers. Alternatively,
supportive evidence might come from more frequent cancer
entities analyzing the impact of variations in DNA repair on
the course of disease. For example, in a large study of lung
cancer patients, the authors detected 15 nonsynonomous
SNPs associated with prognosis (Matakidou et al., 2007);
these primarily mapped to the NER and BER repair pathways,
and ERCC5 p.Asp1104His was among the most signifi-
cant ones. Thus, ERCC5 p.Asp1104His seems to be asso-
ciated with prognosis in different cancer entities. Notably, in
contrast to a previous report by Di Lucca et al. (2010), we did
not find an association between ERCC5 p.Asp1104His—nor
any other of our analyzed—genotypes and Breslow thickness.
Indeed, in multivariate analysis with tumor class instead of
tumor stage, we obtained the same results (data not shown).
To date, all SNPs associated with prognosis belong to the
NER and BER pathways. This notion is further corroborated
by the observation that in early small cell lung cancer patients
a higher expression of DNA synthesis and repair enzymes
RRM1 and ERCC1 in the tumors was associated with a better
overall survival (Zheng et al., 2007). However, the picture is
getting more complex as it has recently been demonstrated
that primary melanomas with poor prognosis overexpress
DNA repair genes (Kauffmann et al., 2008). Indeed, the
majority of these overexpressed genes code for proteins
involved in rescuing stalled DNA replication forks, DNA
double-strand break/interstrand crosslink repair, and telo-
mere maintenance. Similar results were obtained in a larger
study, in which overexpression of DNA repair genes and
genes involved in cell cycle progression was observed in
samples of relapsing compared with nonrelapsing patients
(Jewell et al., 2010). Thus, it seems that a defective or
impaired DNA repair system can contribute to the initiation
of tumors, whereas in the tumor stage patients whose tumors
express larger amounts of DNA repair enzymes present with
a faster relapse. This overexpression of DNA repair genes
might allow the fast-growing cancer cells to replicate more
correctly and thereby to prevent severe, i.e., deleterious,
DNA damage. Somehow surprisingly, however, metastatic
sites often demonstrate higher levels of genetic instability
(Balazs et al., 2001), and in mice the metastatic potential of
tumor cells is associated with increasing genetic instability
(Cifone and Fidler, 1981). As it is known that E2F integrates
cell cycle progression with DNA repair (Ren et al., 2002),
overexpression of DNA repair genes can at least in part be
ascribed to increased proliferation.
The precise mechanism of how the ERCC5 and ERCC2
SNPs influence overall survival in cutaneous melanoma
patients remains elusive; as always for disease-associated
SNPs, the cancer phenotype could be altered in two ways:
either directly by altering the DNA repair capacity of the
tumor cell or indirectly by being in linkage disequilibrium
with other disease-modulating alleles. ERCC5 and ERCC2 are
core proteins of the NER pathway and therefore play crucial
roles in the correction of cyclobutane pyrimidine dimers, 6–4
photoproducts, and bulky adducts induced by chemical
agents (Costa et al., 2003). The potential of amino-acid
substitutions encoded by SNPs to impact protein structure
and activity can be predicted by two different algorithms: i.e.,
SIFT (Sorting Intolerant from Tolerant) and PolyPhen (Poly-
morphism Phenotyping). These algorithms are based on
sequence conservation over evolutionary time, the physical
and chemical properties of the exchanged residues, and/or
protein structural domain information. Several benchmarking
studies have demonstrated that these algorithms predict pro-
tein function very correctly (reviewed in Xi et al., 2004). Both
the SIFT and the PolyPhen algorithms estimate the His
substitution of Asp at codon 1104 of ERCC5 as intolerant or
possible damaging, whereas the Lys substitution by Gln at
codon 751 of ERCC2 was predicted by both programs as
benign. However, functional analysis of the respective
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Figure 1. ERCC5 (excision repair cross-complementing rodent repair
deficiency, complementation group 5) p.Asp1104His polymorphism
influences prognosis. Kaplan–Meier survival estimation for 712 melanoma
patients stratified to ERCC5 p.Asp1104His polymorphism (Po0.0001; log-
rank test). The patients (Pts.) at risk are depicted in 20-month intervals.
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Table 3. The 5-year survival rates
Total Women Men
Variables
n
(at risk/events)1
5-year survival
rate (95% CI)2 P-value3
n
(at risk/events)1
5-year survival
rate (95% CI)2 P-value3
n
(at risk/events)1
5-year survival
rate (95% CI)2 P-value3
Gender
Men 414 (246/98) 76 (72–80)
Women 328 (223/55) 82 (78–87) 0.013
Age at onset4
r45 219 (155/36) 84 (79–89) 113 (79/17) 85 (78–92) 106 (76/19) 83 (75–90)
46–60 233 (158/44) 81 (76–86) 94 (69/14) 85 (78–93) 139 (89/30) 78 (71–85)
460 290 (156/73) 73 (68–78) 0.020 121 (75/24) 78 (70–86) 0.499 169 (81/49) 70 (62–77) 0.044
Tumor classification
T1a 202 (147/14) 92 (89–96) 90 (65/4) 95 (90–100) 112 (82/10) 90 (85–96)
T1b 13 (9/1) 92 (78–100) 4 (4/0) 100 (NA) 9 (5/1) 89 (68–100)
T2a 187 (134/18) 90 (86–95) 84 (64/8) 90 (83–96) 103 (70/10) 91 (85–96)
T2b 27 (13/12) 56 (37–76) 9 (5/2) 71 (38–100) 18 (8/10) 50 (27–73)
T3a 126 (84/23) 81 (74–88) 66 (46/12) 82 (72–92) 60 (38/11) 80 (70–91)
T3b 51 (26/13) 72 (60–85) 22 (15/4) 80 (62–98) 29 (11/9) 67 (49–85)
T4a 71 (29/37) 50 (38–61) 30 (12/16) 49 (31–67) 41 (17/21) 50 (34–66)
T4b 27 (8/16) 36 (17–55) o 0.001 9 (3/4) 47 (10–83) o 0.001 18 (5/12) 32 (10–54) o 0.001
Pathological staging
IA 198 (146/11) 94 (90–97) 87 (64/2) 97 (94–100) 111 (82/9) 91 (86–97)
IB 183 (132/16) 91 (87–95) 77 (61/6) 91 (85–98) 106 (71/10) 91 (85–97)
IIA 134 (87/26) 79 (72–86) 65 (46/9) 85 (75–94) 69 (41/17) 74 (64–85)
IIB 96 (51/30) 69 (60–79) 45 (26/14) 70 (56–84) 51 (25/16) 69 (56–82)
IIC 13 (6/5) 57 (28–86) 2 (1/0) 100 11 (5/5) 52 (21–83)
IIIA 32 (16/16) 55 (38–73) 15 (9/6) 67 (43–91) 17 (7/10) 44 (20–68)
IIIB 44 (11/28) 33 (19–48) 18 (6/10) 40 (16–64) 26 (5/18) 28 (9–44)
IIIC 5 (0/4) 0 (NA) 3 (0/2) 0 (NA) 2 (0/2) 0 (NA)
IV 9 (1/8) 11 (0–32) o 0.001 3 (1/2) 33 (0–87) o0.001 6 (0/6) 0 (NA) o 0.001
ERCC5 p.Asp1104His
GG 449 (296/77) 82 (79–86) 204 (146/27) 86 (81–91) 244 (150/48) 79 (74–85)
GC 206 (130/46) 77 (72–83) 91 (59/16) 81 (72–89) 115 (71/28) 75 (67–83)
CC 57 (26/23) 56 (42–70) o0.001 23 (12/9) 57 (38–80) 0.005 33 (14/14) 53 (35–72) 0.024
ERCC2 p.Lys751Gln
AA 285 (190/52) 82 (77–86) 122 (81/19) 84 (77–91) 163 (109/33) 80 (74–86)
AC 329 (203/67) 79 (74–83) 148 (104/22) 85 (79–91) 181 (99/45) 74 (68–81)
CC 98 (59/27) 72 (62–81) 0.068 48 (32/11) 76 (64–89) 0.468 50 (27/16) 67 (54–80) 0.220
XPC p.Lys939Gln
AA 238 (150/48) 79 (74–85) 108 (73/19) 82 (75–90) 130 (77/29) 77 (69–84)
CA 295 (186/64) 78 (73–83) 129 (88/22) 82 (76–89) 166 (98/42) 74 (67–81)
CC 113 (64/29) 73 (65–82) 0.528 52 (30/11) 73 (61–87) 0.703 61 (34/18) 71 (60–83) 0.725
Table 3 continued on the following page
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amino-acid substitutions is still the gold standard. To this end,
we recently demonstrated for XPG Asp1104His that TT¼T
dimer repair was nonsignificantly lower in heterozygotes
compared with the homozygous wild type (Kumar et al.,
2003); furthermore, we demonstrated an association between
this SNP and the level of single-strand breaks (Vodicka et al.,
2004). In contrast, for ERCC2 751 variant proteins no
difference in NER activity was detectable (Laine et al.,
2007). This observation, on one hand, confirms the results of
the prediction algorithms and, on the other hand, argues that
there is no causal relationship between ERCC2 p.Lys751Gln
polymorphism and reduced DNA repair (Clarkson and
Wood, 2005). However, Wolfe et al. (2007) recently demon-
strated that the minor allele of ERCC2 751 is associated with
decreased constitutive ERCC2 mRNA levels caused by an
altered mRNA secondary structure. This reduced expression
of the mRNA may explain the increased number of DNA
adducts in individuals carrying Gln alleles suggesting lower
DNA repair capacity in these individuals (reviewed in
Benhamou and Sarasin, 2005).
It should be further noted that besides their function in
NER, ERCC2 is involved in transcriptional regulation
(Schaeffer et al., 1993), and ERCC5 acts as a cofactor for a
DNA glycosylase; an enzyme that removes oxidized pyrimi-
dines from DNA. Moreover, ERCC5 has also been involved in
both transcription-coupled repair and RNA transcription itself
(Clarkson, 2003). The SNPs in these genes may therefore
affect not only NER, but also any of these functions.
Table 3. Continued
Total Women Men
Variables
n
(at risk/events)1
5-year survival
rate (95% CI)2 P-value3
n
(at risk/events)1
5-year survival
rate (95% CI)2 P-value3
n
(at risk/events)1
5-year survival
rate (95% CI)2 P-value3
XPC p.Ala499Val
CC 389 (238/83) 78 (73–82) 168 (109/28) 82 (76–88) 221 (129/55) 75 (69–80)
CT 236 (148/50) 78 (73–84) 104 (75/15) 85 (78–92) 132 (73/35) 73 (65–81)
TT 56 (38/11) 81 (71–92) 0.970 32 (22/7) 80 (66–94) 0.601 24 (16/4) 83 (67–98) 0.601
XRCC1 p.Arg399Gln
GG 303 (188/59) 80 (75–84) 139 (87/25) 80 (73–87) 164 (101/34) 79 (73–85)
GA 302 (188/67) 77 (73–82) 133 (98/21) 85 (79–91) 169 (90/46) 71 (64–78)
AA 82 (56/13) 83 (74–91) 0.499 38 (27/5) 86 (74–97) 0.622 44 (29/8) 81 (69–93) 0.329
XRCC3 p.Thr241Met
CC 283 (178/64) 77 (72–82) 118 (79/24) 79 (71–87) 165 (99/40) 75 (69–82)
CT 300 (191/61) 79 (74–83) 142 (96/24) 82 (76–89) 158 (95/37) 75 (68–82)
TT 113 (71/21) 82 (74–89) 0.642 54 (40/5) 90 (81–98) 0.193 59 (31/16) 75 (63–86) 0.839
APEX1 p.Asp148Glu
TT 189 (117/35) 80 (74–86) 70 (43/10) 83 (73–93) 119 (74/25) 78 (70–86)
TG 324 (209/75) 77 (73–82) 155 (111/29) 82 (75–88) 169 (98/46) 73 (67–80)
GG 164 (100/31) 80 (74–86) 0.420 74 (49/9) 87 (79–95) 0.549 90 (51/22) 74 (65–83) 0.362
NBN p.Glu185Gln
GG 329 (204/70) 78 (73–83) 146 (96/27) 80 (74–87) 183 (108/43) 76 (70–82)
CG 282 (178/57) 79 (74–84) 120 (80/19) 83 (76–90) 162 (98/38) 76 (69–83)
CC 68 (44/16) 79 (69–89) 0.727 38 (29/5) 89 (78–99) 0.774 30 (15/11) 66 (49–83) 0.139
Abbreviations: AA, amino acid; APEX1, APEX nuclease (multifunctional DNA repair enzyme) 1; CI, confidence interval; ERCC5, excision repair cross-
complementing rodent repair deficiency, complementation group 5; NBN, Nijmegen break syndrome mutated gene; SNP, single-nucleotide polymorphism;
XPC, xeroderma pigmentosum complementation group C; XRCC, X-ray repair complementing defective repair in Chinese hamster cells.
1Given is the total number of patients (N) as well as those who were observed for 45 years (at risk) and those who died within 5 years after diagnosis
(events).
2The 5-year survival rates were determined by Kaplan–Meier estimations that comprise also those patients censored within 5 years.
3P-values were calculated by the log-rank test.
4The patient cohort was divided into three groups according to age at onset in such a way that almost equipollent groups resulted.
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In conclusion, in this study we identified ERCC5 p.As-
p1104His and ERCC2 p.Lys751Gln as independent prognos-
tic factors for the clinical course of melanoma. Whether
these SNPs impact the prognosis of melanoma directly
via alteration of DNA repair efficacy or by other, possibly
indirect, mechanisms has to be addressed by future studies.
In any case, identification of prognostic factors will help
to individualize and optimize medical care of patients; i.e.,
high-risk patients should receive a closer follow-up and
should be considered for adjuvant therapy.
PATIENTS AND METHODS
Patients and sera
Serum samples were selected from frozen serum banks hosted by
Skin Cancer Unit, Mannheim and the Department of Dermatology,
Wuerzburg. Serum samples to be included in the analysis were
chosen randomly but selected to meet the following criteria: (1)
histological confirmation of primary cutaneous melanoma, (2)
patient of Caucasian origin, and (3) availability of extended
information of the medical history, primary tumor characteristics,
as well as patient follow-up. The only exclusion criteria were sera
from patients with secondary malignancies or in situ melanoma. The
detailed patient characteristics are given in Table 1. All serum
samples were obtained and processed following a standardized
protocol. Briefly, blood was drawn into gel-coated serum tubes
(Sarstedt, Nuembrecht, Germany) and allowed to clot at room
temperature for 30–60minutes. After centrifugation, the serum phase
was harvested and subsequently frozen without any additives at
20 1C. All measures were performed with the approval of the
institutional review board after patients’ informed consent and in
adherence to the Declaration of Helsinki Principles.
Genotyping
DNA was extracted from 200 ml serum of each cryopreserved sample
with the QIAamp DNA mini kit (Qiagen, Hilden, Germany) as
described by the manufacturer and genotyped for eight different
Gender Female
Male
45
46 to 60
> 60
T1a
T2a
T3a
T4a
T4b
IA
IIA
IIB
IIC
IIIA
IIIB
IIIC
IV
GG
GC
CC
AA
AC
CC
CC
CT
TT
TT
TG
GG
GG
GC
CC
CC
CT
TT
AA
GA
GG
AA
AC
CC
IB
T3b
T2b
T1b
Age
Tumor classification
Stage at diagnosis
ERCC5 p.Asp1104His
ERCC2 p.Lys751Gln 
XRCC3 p.Thr241Met
APEX p.Asp148Glu 
NBN p.Glu185Gln
XPC p.Ala499Val
XRCC1 p.Arg399Gln
XPC p.Lys939Gln
0 1 2 3 4 5 6 7 8 9 10
Univariate HR and 95% CI1 P-value
15.9
15.7
14.2 (7–28.6)
11.7
23.3
19.8
20.6 (10.3–41.2)
76 (23.5–245.6)
72 (28.8–180.2)
0.029
0.475
0.008
0.962
0.644
0.368
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
0.141
0.401
0.035
0.595
0.224
0.428
0.947
0.782
0.824
0.734
0.639
0.705
0.386
0.751
0.219
< 0.001
0.007
< 0.001
< 0.001
< 0.001
Figure 2. Univariate hazard ratios (HRs) for overall survival. All factors analyzed are depicted. Dots represent the HRs, lines the 95% confidence intervals (CIs).
In cases where the HRs and/or the CIs are beyond the depicted range, the values are given. A polymorphism is relevant when the respective CI does not cross the
value 1. 1Patient numbers for each analysis are given in Table 1 and Table 2, respectively.
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SNPs in DNA repair genes including the NER genes XPC (A4C;
p.Lys939Gln; rs2228001), XPC (C4T; p.Ala499Val; rs2228000),
ERCC2 (A4C; p.Lys751Gln; rs13181), and ERCC5 (G4C; p.As-
p1104His; rs17655); the BER genes APEX1 (T4G; p.Asp148Glu;
rs1130409) and XRCC1 (G4A; p.Arg399Gln; rs25487); and the
double-strand break repair genes XRCC3 (C4T; p.Thr241Met;
rs861539) and NBN (G4C; p.Glu185Gln; rs1805794). All these
polymorphisms included in the study were nonsynonymous and
have minor allele frequencies 40.2 (Table 2). Genotyping was
performed by the 50 nuclease allelic discrimination assay in TaqMan
technology (Applied Biosystems, Foster City, CA). TaqMan primers
and probes were purchased from Applied Biosystems as assays on
demand (C_16018061_10 for rs2228001 and C_622564_10 for
rs861539) or by own design for all others (Supplementary Table S1
online). PCR was performed in 5 ml volume reaction using 5 ng DNA
as template, master mix (Applied Biosystems), and 0.5 probe/
primer mix. The initial temperature conditions for PCR were set at
50 1C for 2minutes and 95 1C for 10minutes followed by 40–45
cycles at 92 1C for 15 seconds and 60 1C for 1minute. Genotyping on
amplified PCR products was scored by differences in VIC and
5-carboxyfluorescein, succinimidyl ester (FAM) fluorescent level in
plate read operation on ABI PRISM 7900HT sequence detection system
(Applied Biosystems) using SDS 1.2 software (Applied Biosystems).
Genotyping results from allelic discrimination assays were randomly
verified by DNA sequencing. The sequencing reactions were performed
using BigDyeR Terminator Cycle Sequencing Kit (Applied Biosystems)
in a 10ml volume containing PCR product pre-treated with ExoSapIT
(USB Corporation, Cleveland, OH), 5 Sequencing buffer (Applied
Biosystems), and a sequencing primer. The temperature conditions
set for sequencing reactions were 96 1C for 2minutes followed by
27 cycles at 96 1C for 30 seconds, 54 1C for 10 seconds, and 60 1C
for 4minutes. Sequencing reaction products were precipitated with
2-propanol, washed with 75% ethanol, resuspended in 25 ml
water, and loaded onto ABI prism 3100 Genetic analyzer (Applied
Biosystems). Primary sequencing data were analyzed using the
accompanied sequence analysis program (Applied Biosystems).
Statistical methods
Data were analyzed by the statistic software R (version 2.8) available
at http://www.r-project.org using the libraries ‘‘survival’’ and
‘‘genetics.’’ Age was categorized into three groups (age p45,
46–60, and 460 years). Each genotype-variable was dichotomized
into three individual variables. For univariate analyses, the
Kaplan–Meier method was used to compare survival times between
groups. Differences in 5-year survival rates and survival times were
assessed by the log-rank test. In addition, for univariate as well as
Multivariate HR and 95% CI1
Gender Female
Male
45
46 to 60
>60
IA
IB
IIA
IIB/C
IIIA
IIIB/C
IV
GG
GC
CC
TT
TG
GG
CC
CT
TT
TT
TG
GG
GG
GC
CC
CC
CT
TT
AA
GA
GG
AA
AC
CC
Age
Stage at diagnosis
ERCC5 p. Asp1104His
ERCC2 p.Lys751Gln
XRCC3 p.Thr241Met
APEX1 p.Asp148Glu
NBN p.Glu185Gln
XPC p.Ala499Val
XRCC1 Arg399Gln
XPC p.Lys939Gln
P-value
11.5
23
24.2 (10.4–56.4)
321.2 (86–1200.4)
109876543210
0.001
0.328
0.009
0.269
0.006
< 0.001
< 0.001
< 0.001
< 0.001
< 0.161
0.009
0.292
0.568
0.312
0.432
0.543
0.151
0.785
0.439
0.494
0.994
0.966
0.436
< 0.001
0.060
Figure 3. Multivariate hazard ratios (HRs) for overall survival. Besides the eight DNA repair single-nucleotide polymorphisms (SNPs), gender, categorized age,
and stage at diagnosis were included. Dots represent the HRs, lines the 95% confidence intervals (CIs). In cases where the HRs and/or the CIs are beyond the
depicted range, the values are given. A polymorphism is relevant when the respective CI does not cross the value 1. 1This analysis is based on 498 patients since
244 patients had to be omitted due to absence of information on primary tumor or missing genotype of at least one of the analyzed SNPs.
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multivariate analyses, Cox’s proportional hazards regression model
was applied with dichotomized variables. As the majority of the
melanoma-associated events happen within the first 5 years after
diagnosis, close follow-up according to the German guidelines is
only recommended for this time period (Garbe et al., 2007).
Consequently, we censored our patient cohort after this period. To
scrutinize and validate relevant variables, multiple analyses includ-
ing backward and forward stepwise Cox regressions were performed.
Linkage disequilibrium was calculated with the function linkage
disequilibrium of the library ‘‘genetics.’’ All presented multivariate
regression models were evaluated by bootstrap methods according
to the recommendations of Altman and Andersen (1989).
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